ProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of ProMetic Life Sciences Inc. (TSE:PLI) have been given an average rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is C$3.50.

A number of equities analysts have commented on the stock. National Bank Financial cut their price objective on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 15th. Royal Bank Of Canada cut their target price on shares of ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research note on Wednesday, August 16th. TD Securities cut their target price on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research note on Wednesday, August 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ProMetic Life Sciences in a research note on Monday, November 20th.

Shares of ProMetic Life Sciences (TSE:PLI) traded up C$0.01 during mid-day trading on Friday, reaching C$1.25. 354,817 shares of the company’s stock were exchanged, compared to its average volume of 995,467. ProMetic Life Sciences has a 52-week low of C$1.12 and a 52-week high of C$2.64.

In related news, Director Pierre Laurin sold 82,738 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of C$1.44, for a total transaction of C$119,142.72. Also, insider Jonathan Booth acquired 75,000 shares of the company’s stock in a transaction that occurred on Friday, October 6th. The shares were acquired at an average price of C$1.21 per share, for a total transaction of C$90,750.00. In the last 90 days, insiders bought 93,525 shares of company stock worth $117,066.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/12/08/prometic-life-sciences-inc-pli-given-consensus-recommendation-of-buy-by-brokerages.html.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply